Order No. 818: Pushing 80% of China's Cell Therapy Companies Out

Regulatory shock in Nansha

A sweeping new administrative rule — the "818 Order" (the Regulations on Clinical Research and Clinical Translation of Biomedical New Technologies) — is reshaping China's cell-therapy landscape and, reportedly, forcing the vast majority of small players to exit. The rule, passed in September and effective from May 1, 2026, requires stem‑cell clinical work to be conducted only in top‑tier tertiary hospitals (三级甲等), subject to strict national approval, staffed by professional ethics and academic committees, and to retain research data for decades — 30 years for clinical data and permanent retention for genetic data. The consequences were visible in Guangdong Medical Valley · Nansha Life Science Park (广东医谷·南沙生命科学园), a once‑bustling cluster that industry insiders say has been staging a mass "clearance" of cell‑therapy firms ahead of the deadline. Who can survive when clinical access, revenue models and data burdens all change overnight?

What the order targets — and why

China's cell‑therapy sector has long run on a dual‑track regulatory model: either pursue new‑drug approval with long, costly trials, or operate under the medical‑technology pathway that lets enterprises lead IND‑style projects in cooperation with hospitals — a route critics say invited overstated claims and quasi‑medical consumer services. The new rules close that loophole. Violations now carry steep penalties — minimum fines reportedly of one million yuan and up to 20 times unlawful gains — and the operational bar is high: stable funding, institutional hospital partners and robust quality systems. The move targets widespread misuse of "stem‑cell" marketing in beauty clinics and unregistered treatments for serious disease, episodes that have drawn domestic outrage after several high‑profile patient harms.

Winners, losers and market consolidation

Not every company will vanish. It has been reported that only around 5% of current stem‑cell firms have the capacity to meet fullchain compliance; industry voices suggest more than 80% will shutter, transfer assets, or pause operations ahead of May. That accelerates consolidation in favour of established players and large hospitals. Firms such as Zhongyuan Xiehe (中源协和), Jiuzhitang (九芝堂) and Tasly (天士力) — all pursuing regulated clinical programs and manufacturing platforms — stand to gain market share as smaller labs and consumer‑facing clinics retreat. Meanwhile, Beijing hospitals are moving to internalise capability: Peking University Third Hospital has publicly announced plans for its own clinical stem‑cell centre and in‑house GMP production, undercutting outsourced providers. The result? A more concentrated, clinically anchored ecosystem — but one that will be more expensive and slower to commercialize.

Policy context and global implications

Domestically, regulators characterise 818 as closing safety gaps while promoting legitimate innovation — and it dovetails with a recent revision of China’s Drug Administration Law implementation rules (the so‑called "828 Order") that clarifies pathways for "live" biological drugs, marketing‑authorization holders and conditional approvals. Internationally, tighter domestic control over cell and gene therapies comes amid heightened geopolitics around biotech — export controls, supply‑chain scrutiny and Western restrictions on sensitive technologies — making indigenous clinical and manufacturing capacity politically as well as economically strategic. For Western observers wondering whether China is decelerating biotech hope or professionalizing it, the answer is: both. The immediate effect is pain for thousands of small companies; the longer‑term effect may be a smaller number of better‑regulated clinical programs — but at what cost to innovation diversity and patient access remains an open question.